Scarica l'app Stockscreener
62.53
1.63%
1.00
Dopo l'orario di chiusura:
62.53
Precedente Chiudi:
$61.53
Aprire:
$61.7
Volume 24 ore:
2.19M
Relative Volume:
1.50
Capitalizzazione di mercato:
$12.70B
Reddito:
$2.75B
Utile/perdita netta:
$322.29M
Rapporto P/E:
37.44
EPS:
1.67
Flusso di cassa netto:
$300.88M
1 W Prestazione:
-2.01%
1M Prestazione:
-4.77%
6M Prestazione:
-25.64%
1 anno Prestazione:
-32.22%
Intervallo 1D:
$61.56
$63.03
Intervallo di 1 settimana:
$60.63
$64.72
Portata 52W:
$60.63
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
62.53 | 12.70B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Sabry Lays Out BioMarin’s New Business Development Plan - News & Insights
Earnings are growing at BioMarin Pharmaceutical (NASDAQ:BMRN) but shareholders still don't like its prospects - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 - Insider Monkey
10 Under-the-Radar Stocks with Massive Upside for 2025 - Insider Monkey
Avanza Fonder AB Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Sees Large Decrease in Short Interest - MarketBeat
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Down 3%Should You Sell? - MarketBeat
BioMarin Pharmaceutical Target of Unusually High Options Trading (NASDAQ:BMRN) - MarketBeat
BioMarin stock touches 52-week low at $60.77 amid challenges - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 52-Week LowWhat's Next? - MarketBeat
BioMarin files UPC’s first pharma infringement suit in over three months - IAM
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Simply Wall St
Assenagon Asset Management S.A. Grows Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Wedmont Private Capital Makes New $430,000 Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Down 3%What's Next? - MarketBeat
UTHR: 3 Niche Biotech Stocks Redefining Innovation - StockNews.com
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
5 Biotech Stocks Worth Adding to Your Portfolio in 2025 - Yahoo Finance
Goldman Sachs maintains Buy on BioMarin shares - Investing.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $94.20 Consensus Target Price from Analysts - MarketBeat
BioMarin sues Ascendis Pharma over patent infringement By Investing.com - Investing.com Canada
BioMarin sues Ascendis Pharma over patent infringement - Investing.com
BioMarin Takes Legal Action Against Ascendis Over CNP Patent in European Court - StockTitan
Wall Street Analysts Predict a 45.86% Upside in BioMarin (BMRN): Here's What You Should Know - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Zacks Research Has Optimistic Outlook of BMRN Q2 Earnings - MarketBeat
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - MSN
Zacks Research Analysts Lift Earnings Estimates for BMRN - MarketBeat
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Trading 2.4% HigherStill a Buy? - MarketBeat
XBI, NBIX, GILD, BMRN: Large Outflows Detected at ETF - Nasdaq
Zacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical - Yahoo Finance
BMRNBioMarin Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA - PR Newswire
BioMarin CEO to Present at J.P. Morgan Healthcare Conference 2024 - StockTitan
BioMarin plans €60m expansion at Shanbally site - The Southern Star
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) - Yahoo Finance
BMRN or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI - GlobeNewswire Inc.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Down 9.4% in December - MarketBeat
Sangamo Shares Nosedive as Pfizer Drops Hemophilia Drug Pact - Wall Street Pit
Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet? - Simply Wall St
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Position Trimmed by Principal Financial Group Inc. - MarketBeat
First Week of February 2025 Options Trading For BioMarin Pharmaceutical (BMRN) - Nasdaq
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock? - MSN
Stifel Financial Corp Decreases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $94.20 Average Price Target from Brokerages - MarketBeat
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):